JP MORGAN/PUT/MEDTRONIC/80/0.1/19.07.24 Stock

Warrant

DE000JK186D9

Market Closed - Börse Stuttgart 02:52:03 2024-07-05 EDT
0.25 EUR -7.41% Intraday chart for JP MORGAN/PUT/MEDTRONIC/80/0.1/19.07.24
Current month+31.58%
1 month+197.62%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.25 -7.41%
24-07-04 0.27 +3.85%
24-07-03 0.26 -10.34%
24-07-02 0.29 +61.11%
24-07-01 0.18 -5.26%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 02:52 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying MEDTRONIC PLC
Issuer J.P. Morgan
WKN JK186D
ISINDE000JK186D9
Date issued 2024-02-06
Strike 80 $
Maturity 2024-07-19 (13 Days)
Parity 10 : 1
Emission price 0.21
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.37
Lowest since issue 0.071
Spread 0.01
Spread %4.17%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
77.61 USD
Average target price
94.02 USD
Spread / Average Target
+21.15%
Consensus